Recro Pharma (REPH) Misses Q1 EPS by 5c

Recro Pharma (NASDAQ: REPH) reported Q1 EPS of ($0.71), $0.05 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $17.7 million versus the consensus estimate of $13 million.

For earnings history and earnings-related data on Recro Pharma (REPH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c
• Reading (RDI) Tops Q2 EPS by 4c